Recruiting Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors NCT06171750 Conditions Advanced Solid Tumor, Bronchial Neoplasms, Carcinoma, Bronchogenic, +23 more Locations National Cancer Institute — Bethesda, Maryland, United States Massachusetts General Hospital — Boston, Massachusetts, United States Providence Cancer Institute — Portland, Oregon, United States Hillman Cancer Center — Pittsburgh, Pennsylvania, United States View more locations Show fewer locations Loading locations... View Trial Details
